Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFMW) EBITDA (2016 - 2025)

Historic EBITDA for Sunshine Biopharma (SBFMW) over the last 13 years, with Q3 2025 value amounting to -$1.5 million.

  • Sunshine Biopharma's EBITDA fell 32911.81% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.5 million, marking a year-over-year decrease of 5209.38%. This contributed to the annual value of -$6.7 million for FY2024, which is 6768.73% down from last year.
  • According to the latest figures from Q3 2025, Sunshine Biopharma's EBITDA is -$1.5 million, which was down 32911.81% from -$686277.0 recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's EBITDA peaked at $701988.0 during Q4 2021, and registered a low of -$23.3 million during Q4 2022.
  • Its 5-year average for EBITDA is -$2.8 million, with a median of -$1.3 million in 2024.
  • The largest annual percentage gain for Sunshine Biopharma's EBITDA in the last 5 years was 16485.43% (2021), contrasted with its biggest fall of 637195.5% (2021).
  • Sunshine Biopharma's EBITDA (Quarter) stood at $701988.0 in 2021, then plummeted by 3414.95% to -$23.3 million in 2022, then soared by 96.74% to -$758468.0 in 2023, then crashed by 316.2% to -$3.2 million in 2024, then soared by 52.94% to -$1.5 million in 2025.
  • Its EBITDA was -$1.5 million in Q3 2025, compared to -$686277.0 in Q2 2025 and -$1.2 million in Q1 2025.